Haleon (NYSE:HLN) Stock Rating Reaffirmed by Argus

Haleon (NYSE:HLN)‘s stock had its “buy” rating restated by stock analysts at Argus in a report issued on Tuesday, Benzinga reports. They currently have a $10.00 price target on the stock. Argus’ price target would indicate a potential upside of 18.76% from the company’s previous close.

Haleon Stock Down 0.1 %

NYSE:HLN traded down $0.01 during midday trading on Tuesday, reaching $8.42. The company had a trading volume of 5,906,024 shares, compared to its average volume of 5,553,531. The firm has a market capitalization of $38.88 billion, a price-to-earnings ratio of 29.96, a PEG ratio of 2.17 and a beta of 0.30. The stock’s fifty day simple moving average is $8.32 and its 200-day simple moving average is $8.28. Haleon has a 12-month low of $7.70 and a 12-month high of $9.05. The company has a current ratio of 1.04, a quick ratio of 0.73 and a debt-to-equity ratio of 0.53.

Institutional Trading of Haleon

Institutional investors and hedge funds have recently made changes to their positions in the company. Farther Finance Advisors LLC increased its position in Haleon by 79.3% in the 2nd quarter. Farther Finance Advisors LLC now owns 2,986 shares of the company’s stock valued at $25,000 after acquiring an additional 1,321 shares during the period. Washington Trust Advisors Inc. increased its position in Haleon by 353.3% in the 3rd quarter. Washington Trust Advisors Inc. now owns 2,960 shares of the company’s stock valued at $25,000 after acquiring an additional 2,307 shares during the period. CoreFirst Bank & Trust acquired a new position in Haleon in the 4th quarter valued at about $26,000. Barclays PLC increased its position in Haleon by 56.4% in the 2nd quarter. Barclays PLC now owns 3,317 shares of the company’s stock valued at $28,000 after acquiring an additional 1,196 shares during the period. Finally, Resurgent Financial Advisors LLC acquired a new position in Haleon in the 4th quarter valued at about $29,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.